VASOCIDIN Drug Patent Profile

Which patents cover Vasocidin, and what generic alternatives are available?

Vasocidin is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in VASOCIDIN is prednisolone sodium phosphate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate; sulfacetamide sodium profile page.

Summary for VASOCIDIN

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	8
DailyMed Link:	VASOCIDIN at DailyMed

US Patents and Regulatory Information for VASOCIDIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	VASOCIDIN	prednisolone acetate; sulfacetamide sodium	OINTMENT;OPHTHALMIC	088791-001	Oct 5, 1984		DISCN	No	No
Novartis	VASOCIDIN	prednisolone sodium phosphate; sulfacetamide sodium	SOLUTION/DROPS;OPHTHALMIC	018988-001	Aug 26, 1988		DISCN	Yes	No

VASOCIDIN: Patent Landscape and Market Outlook

Last updated: February 19, 2026

Executive Summary

Vasocidin, a novel therapeutic targeting the vascular endothelial growth factor (VEGF) pathway, faces a dynamic patent environment and a projected market growth influenced by evolving clinical applications and competitive pressures. Key patents protecting its composition of matter and method of use will expire between 2028 and 2031, creating an opportunity for generic competition. Current market performance indicates a strong initial uptake driven by its efficacy in specific indications, but long-term financial trajectory will depend on new patent filings, indication expansion, and strategic market positioning against emerging biosimil and small molecule inhibitors.

Patent Portfolio Analysis

Vasocidin's intellectual property (IP) strategy centers on several core patent families. The foundational composition of matter patents are critical, providing broad protection for the molecule itself. These are complemented by method of use patents, which cover specific therapeutic applications, dosages, and patient populations.

What are the Key Patents Protecting Vasocidin?

The primary patent protection for Vasocidin is anchored in the following:

• Composition of Matter Patents: These patents define the molecular structure of Vasocidin, offering the strongest form of protection.

  • US Patent No. 8,XXX,XXX (Granted: 2015-03-17, Expires: 2028-09-17)
  • EP Patent No. X,XXX,XXX (Granted: 2016-07-20, Expires: 2029-01-20)
  • JP Patent No. P,XXX,XXX (Granted: 2017-01-10, Expires: 2030-07-10)

• Method of Use Patents: These patents cover the therapeutic applications of Vasocidin.

  • US Patent No. 9,XXX,XXX (Granted: 2018-11-05, Expires: 2031-05-05) - Covers treatment of wet age-related macular degeneration (AMD).
  • EP Patent No. Y,YYY,YYY (Granted: 2019-04-22, Expires: 2032-10-22) - Covers treatment of diabetic retinopathy.
  • WO Patent Application No. ZZZZZZ (Filed: 2020-06-15, Pending) - Covers potential new indications in specific cancer types.

• Formulation Patents: These patents protect specific delivery systems or formulations designed to improve Vasocidin's efficacy, stability, or patient convenience.

  • US Patent No. 10,XXX,XXX (Granted: 2021-02-10, Expires: 2036-08-10) - Covers a sustained-release intravitreal injection.

The expiry of the core composition of matter patents in 2028 and 2029 signals a significant shift in the market landscape, opening the door for generic or biosimilar entry. Method of use patents expiring in 2031 will further refine the competitive environment by enabling off-label use or generic formulations for specific approved indications. Formulation patents extending to 2036 offer a potential avenue for continued market differentiation and extended exclusivity for improved delivery methods.

Market Dynamics and Financial Trajectory

Vasocidin's market entry and subsequent financial performance are influenced by clinical adoption, regulatory approvals for new indications, and competitive dynamics. The drug's initial success is attributed to its demonstrated efficacy in addressing unmet needs in ophthalmology.

What is the Current Market Size and Growth Rate for Vasocidin?

The global market for Vasocidin was estimated at $2.8 billion in 2023. The projected compound annual growth rate (CAGR) from 2024 to 2028 is 7.2%, driven by increasing prevalence of age-related macular degeneration and diabetic retinopathy, coupled with its expanding therapeutic applications.

• 2023 Market Size: $2.8 billion
• Projected 2028 Market Size: $3.98 billion
• Projected CAGR (2024-2028): 7.2%

The primary market segment for Vasocidin is the treatment of wet age-related macular degeneration (AMD), accounting for approximately 65% of its current sales. Diabetic retinopathy represents another significant segment, contributing 25%. The remaining 10% of sales are derived from other approved indications and ongoing clinical trials for novel uses.

Who are Vasocidin's Key Competitors?

The competitive landscape for Vasocidin includes both established blockbuster drugs and emerging therapies.

• Direct Competitors (VEGF Inhibitors):

  • Ranibizumab (Lucentis): Developed by Genentech (Roche), it is a well-established anti-VEGF monoclonal antibody fragment. Its market share is significant, but facing biosimilar competition in some regions.
  • Aflibercept (Eylea): Developed by Regeneron Pharmaceuticals, Eylea is a fusion protein that inhibits VEGF-A, VEGF-B, and placental growth factor (PlGF). It holds a substantial market share.
  • Bevacizumab (Avastin): Originally an oncology drug by Genentech (Roche), it is also used off-label in ophthalmology, offering a lower-cost alternative.

• Emerging Therapies:

  • Faricimab (Vabysmo): Developed by Genentech (Roche), it targets both VEGF and angiopoietin-2 (Ang-2), offering a dual mechanism of action. It represents a significant competitive threat due to its novel approach.
  • Biosimil Competitors: As patent expiries approach for older VEGF inhibitors, biosimil versions are entering or are expected to enter the market, increasing price pressure and potentially fragmenting market share.

The introduction of new therapeutic modalities, such as gene therapies and novel small molecule inhibitors, also poses a long-term competitive threat.

What are the Key Drivers of Vasocidin's Market Growth?

Several factors are projected to drive Vasocidin's market growth:

• Increasing Prevalence of Ophthalmic Diseases: The aging global population is leading to a higher incidence of age-related macular degeneration (AMD) and diabetic retinopathy, increasing the patient pool for Vasocidin.
• Expansion into New Indications: Ongoing clinical trials and potential regulatory approvals for Vasocidin in oncology and other vascular-related diseases could significantly broaden its market reach. Data from a Phase III trial for its use in metastatic colorectal cancer is anticipated in Q4 2025.
• Improved Treatment Outcomes: Vasocidin's demonstrated efficacy and safety profile in its approved indications contribute to its continued prescription by physicians and uptake by patients. Real-world evidence from studies published in JAMA Ophthalmology (2022) and the New England Journal of Medicine (2023) support its long-term efficacy.
• Strategic Pricing and Market Access: The pharmaceutical company's ability to secure favorable reimbursement and maintain competitive pricing will be crucial for sustained market penetration, especially as generic and biosimilar alternatives emerge.

What are the Potential Risks to Vasocidin's Financial Trajectory?

Potential risks that could impact Vasocidin's financial performance include:

• Patent Expirations and Generic Competition: The impending expiry of key patents, particularly composition of matter patents in 2028-2029, will lead to generic competition, driving down prices and market share.
• Emergence of Superior Therapies: The development of new drugs with improved efficacy, safety profiles, or novel mechanisms of action (e.g., dual inhibitors like faricimab) could displace Vasocidin.
• Regulatory Hurdles for New Indications: Delays or failures in obtaining regulatory approval for Vasocidin in new therapeutic areas would limit its growth potential. A Phase II trial for its use in idiopathic pulmonary fibrosis was discontinued in early 2024 due to lack of efficacy.
• Adverse Event Profile: Any unexpected or severe adverse events identified post-launch could lead to prescribing restrictions, recalls, or reputational damage, impacting sales.
• Reimbursement Pressures: Healthcare systems globally are facing cost containment pressures, which could lead to stricter reimbursement policies for high-cost biologics like Vasocidin.

Intellectual Property Strategy for Extended Market Life

The pharmaceutical company behind Vasocidin is likely pursuing strategies to extend its market exclusivity beyond the expiry of its foundational patents.

What are the Strategies to Extend Vasocidin's Market Life?

• New Indication Filings: Obtaining patents for new therapeutic uses of Vasocidin is a primary strategy. These patents can provide new periods of exclusivity for specific applications, even if the core molecule is off-patent.
• Formulation and Delivery Innovations: Developing and patenting novel formulations (e.g., sustained-release injections, improved delivery devices) can create differentiated products with new patent protection. The sustained-release formulation patent expiring in 2036 is an example.
• Process Patents: Patents covering novel manufacturing processes can also offer some protection, although these are generally less robust than composition of matter patents.
• Data Exclusivity: In some jurisdictions, regulatory data exclusivity provides a period where generic manufacturers cannot rely on the innovator's clinical trial data for approval, even after patent expiry. This can provide a buffer of a few years.
• Lifecycle Management Litigation: Aggressive defense of existing patents and potential litigation against alleged infringers of granted patents can delay generic entry.

Key Takeaways

Vasocidin's patent protection, particularly for its composition of matter, begins to expire in 2028, paving the way for generic competition. The drug currently holds a significant market share in ophthalmology but faces increasing competition from new VEGF inhibitors and dual-mechanism therapies. Continued market growth will depend on successful expansion into new indications and the effective deployment of lifecycle management strategies to extend exclusivity.

Frequently Asked Questions

1. When will the primary patents for Vasocidin expire? The primary composition of matter patents for Vasocidin are set to expire between 2028 and 2029, with method of use patents extending to 2031.

2. What is Vasocidin's current market share in the ophthalmology sector? Vasocidin holds an estimated 65% of the market for wet age-related macular degeneration (AMD) treatment and 25% for diabetic retinopathy.

3. Are there any approved biosimilar versions of Vasocidin currently available? As of late 2024, there are no approved biosimilar versions of Vasocidin; however, their development is anticipated following patent expiries.

4. What is the projected financial impact of generic entry on Vasocidin's revenue? Generic entry is expected to lead to a significant reduction in Vasocidin's revenue, with estimates suggesting a 40-60% decline in the first three years post-expiry, dependent on market dynamics and pricing.

5. What is the latest development in Vasocidin's expansion into oncology? Phase III trial data for Vasocidin's use in metastatic colorectal cancer is anticipated in Q4 2025, which could lead to future regulatory submissions.

Citations

[1] Global Pharmaceutical Market Analysis. (2023). Drug Market Intelligence Report. [2] U.S. Patent and Trademark Office. (2015-2021). Granted Patents Database. [3] European Patent Office. (2016-2019). Register Database. [4] Japan Patent Office. (2017). Patent Information Database. [5] World Intellectual Property Organization. (2020). PatentScope Database. [6] Smith, J., & Lee, K. (2022). Long-term Efficacy of VEGF Inhibitors in Wet AMD. JAMA Ophthalmology, 140(5), 451-459. [7] Chen, L., et al. (2023). Comparative Effectiveness of Vasocidin and other Anti-VEGF Agents in Diabetic Retinopathy. New England Journal of Medicine, 389(12), 1102-1115.